Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI). Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy).

NCT Number	NCT07497399
Lead Sponsor	Johns Hopkins University Collaborators: National Multiple Sclerosis Society, Race to Erase MS
Conditions	Multiple Sclerosis
Enrollment	120 participants
Start Date	2026-04-28
Primary Completion	2030-01 (estimated)
Study Completion	2030-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-17